{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:10:12Z","timestamp":1778649012320,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","award":["UL1-TR-001857"],"award-info":[{"award-number":["UL1-TR-001857"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD028540"],"award-info":[{"award-number":["S10OD028540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR023461"],"award-info":[{"award-number":["S10RR023461"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD011092"],"award-info":[{"award-number":["P51 OD011092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012386","name":"Magee-Womens Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Organon Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008143","name":"Oregon National Primate Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.contraception.2024.110720","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T22:35:51Z","timestamp":1727822151000},"page":"110720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratories"],"prefix":"10.1016","volume":"142","author":[{"given":"Shawnalyn W.","family":"Sunagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee C.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Wichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean N.","family":"Avedissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Erikson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Kernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Mykris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renu","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas D.","family":"Nolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Raymond E.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2024.110720_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2022.109100","article-title":"Variability and quantification of serum medroxyprogesterone acetate levels","volume":"187","author":"Bick","year":"2022","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2024.110720_bib2","first-page":"292","article-title":"Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens","volume":"19","author":"Faupel-Badger","year":"2010","journal-title":"Cancer Epidemiol\u00a0Biomarkers Prev"},{"key":"10.1016\/j.contraception.2024.110720_bib3","first-page":"223","article-title":"Do metabolites account for higher serum steroid hormone levels measured by RIA compared to mass spectrometry?","volume":"484","author":"Stanczyk","year":"2018","journal-title":"Clin\u00a0Chim\u00a0Acta"},{"key":"10.1016\/j.contraception.2024.110720_bib4","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2024.110720_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.contraception.2017.03.004","article-title":"The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users","volume":"95","author":"Lazorwitz","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.contraception.2020.04.011","article-title":"A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users","volume":"102","author":"Lazorwitz","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/QAD.0000000000002308","article-title":"A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda","volume":"33","author":"Patel","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2024.110720_bib8","first-page":"378","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"JAIDS J\u00a0Acquir\u00a0Immune Defic\u00a0Syndr"},{"key":"10.1016\/j.contraception.2024.110720_bib9","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/S2352-3018(19)30155-9","article-title":"Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study","volume":"6","author":"Scarsi","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2024.110720_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.contraception.2018.12.010","article-title":"A sensitive and robust UPLC\u2013MS\/MS method for quantitation of estrogens and progestogens in human serum","volume":"99","author":"Zhang","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/FTD.0b013e31829a10fa","article-title":"A UPLC-MS\/MS method for therapeutic drug monitoring of etonogestrel","volume":"35","author":"Thomas","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.contraception.2024.110720_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2018.01.015","article-title":"Simultaneous quantitation of multiple contraceptive hormones in human serum by LC\u2013MS\/MS","volume":"97","author":"Blue","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.contraception.2021.12.008","article-title":"Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period","volume":"108","author":"Lazorwitz","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib14","first-page":"3003","article-title":"Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART","volume":"74","author":"Neary","year":"2019","journal-title":"J\u00a0Antimicrob\u00a0Chemother"},{"key":"10.1016\/j.contraception.2024.110720_bib15","first-page":"783","article-title":"Influence of genetic variants on steady-state etonogestrel concentrations among contraceptive implant users","volume":"133","author":"Lazorwitz","year":"2019","journal-title":"Obstet\u00a0Gynecol"},{"key":"10.1016\/j.contraception.2024.110720_bib16","unstructured":"US Food and Drug Administration. Bioanalytical method validation guidance for industry biopharmaceutics bioanalytical method validation guidance for industry biopharmaceutics contains nonbinding recommendations [Internet]. 2018. Available from: \u3008http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htmand\/orhttp:\/\/www.fda.gov\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/default.htm\u3009."},{"key":"10.1016\/j.contraception.2024.110720_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.contraception.2024.110720_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.contraception.2024.110720_bib19","unstructured":"European Medicines Agency. Committee for medicinal products for human use ICH guideline M10 on bioanalytical method validation and study sample analysis Step5 [Internet]. 2022. Available from: \u3008www.ema.europa.eu\/contact\u3009."},{"issue":"2","key":"10.1016\/j.contraception.2024.110720_bib20","doi-asserted-by":"crossref","first-page":"242.e1","DOI":"10.1016\/j.ajog.2024.03.001","article-title":"A randomized trial of double verses single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy","volume":"231","author":"Chappell","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2024.110720_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FPC.0000000000000396","article-title":"Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives","volume":"30","author":"Haas","year":"2020","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.contraception.2024.110720_bib22","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.12688\/gatesopenres.12975.2","article-title":"Contraceptive implant failures among women using antiretroviral therapy in western Kenya: a retrospective cohort study","volume":"3","author":"Pfitzer","year":"2020","journal-title":"Gates Open Res"},{"key":"10.1016\/j.contraception.2024.110720_bib23","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(15)00184-8","article-title":"Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study","volume":"2","author":"Patel","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2024.110720_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1752-1947-8-43","article-title":"Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report","volume":"8","author":"Lange","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.contraception.2024.110720_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0010-7824(91)90030-J","article-title":"Clinical trial with 3-keto-desogestrel subdermal implants","volume":"44","author":"D\u00edaz","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2024.110720_bib26","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2024.110720_bib27","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1111\/bcp.15477","article-title":"A population pharmacokinetic model based on HPTN 077 of long\u2010acting injectable cabotegravir for HIV PrEP","volume":"88","author":"Yu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2024.110720_bib28","article-title":"Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP","volume":"6","author":"Han","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.contraception.2024.110720_bib29","unstructured":"University at Buffalo Translational Pharmacology Research Core. Clinical pharmacology quality assurance program [Internet]. 2024 [cited Jul 4, 2024]. Available from: \u3008https:\/\/www.buffalo.edu\/tprc\/section-2\/CPQA.html#:~:text=What%20CPQA%20Does,clinical%20pharmacology%20laboratories%20\u3009\u3008(CPLs)\u3009."},{"key":"10.1016\/j.contraception.2024.110720_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/clpt.2013.62","article-title":"Clinical pharmacology quality assurance for HIV and related infectious diseases research","volume":"93","author":"DiFrancesco","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2024.110720_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/bmm.12.57","article-title":"Repeating tests: different roles in research studies and clinical medicine","volume":"6","author":"Monach","year":"2012","journal-title":"Biomark Med"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424004281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782424004281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:29:59Z","timestamp":1778646599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782424004281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":31,"alternative-id":["S0010782424004281"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110720","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratories","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2024.110720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110720"}}